Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
79 hedge funds and large institutions have $116M invested in Adaptimmune Therapeutics in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 16 increasing their positions, 24 reducing their positions, and 17 closing their positions.
1.28% more ownership
Funds ownership: 64.3% → 65.58% (+1.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
11% less funds holding
Funds holding: 89 → 79 (-10)
14% less capital invested
Capital invested by funds: $134M → $116M (-$18.2M)
33% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 24
59% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$2.64M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$1.73M |
| 3 |
AI
Acuitas Investments
Seattle,
Washington
|
+$403K |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$235K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$151K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$427K |
| 2 |
Renaissance Technologies
New York
|
-$402K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$329K |
| 4 |
Millennium Management
New York
|
-$295K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$254K |
ADAP Hedge Fund Activity: Q3 2023 in Review
79 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q3 2023, worth a combined $116M — down 14% from $134M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ADAP and 7 opened new positions — a net loss of 10 holders — while 24 trimmed existing stakes and 16 added.
The largest buyer was Long Focus Capital Management, adding an estimated $2.64M. The largest seller was Endurant Capital Management, cutting an estimated $427K.
- 79 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q3 2023, down from 89 in Q2 2023.
- Funds reported $116M of Adaptimmune Therapeutics stock for Q3 2023, down 14% quarter-over-quarter.
- 7 funds opened new Adaptimmune Therapeutics positions in Q3 2023 and 17 closed out, a net change of -10 holders.
- The largest Adaptimmune Therapeutics buyer in Q3 2023 was Long Focus Capital Management, an estimated $2.64M added.
- The largest Adaptimmune Therapeutics seller in Q3 2023 was Endurant Capital Management, an estimated $427K sold.
Based on aggregated 13F filings for Q3 2023.